J&J announces IPO prices for consumer spinoff Kenvue

Johnson & Johnson will price shares of its consumer health spinoff Kenvue at $20 to $23 in an initial public offering later this year, the company said in a filing Monday.

J&J said it launched a roadshow for the IPO of more than 151 million shares of common stock.

Goldman Sachs, J.P. Morgan and Bank of America are leading managers for the IPO, the company said.

The company previously said it expects to complete the separation from Kenvue by mid- to late 2023.

This is breaking news. Please check back for updates.